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Abstract
Background: Efavirenz-based antiretroviral therapy (ART) regimens are preferred for treatment of adult HIV-positive
patients co-infected with tuberculosis (HIV/TB). Few studies have compared outcomes among HIV/TB patients
treated with efavirenz or non-efavirenz containing regimens.
Methods: HIV-positive patients aged ≥16 years with a diagnosis of tuberculosis recruited to the TB:HIV study
between Jan 1, 2011, and Dec 31, 2013 in 19 countries in Eastern Europe (EE), Western Europe (WE), and
Latin America (LA) who received ART concomitantly with TB treatment were included. Patients either received
efavirenz-containing ART starting between 15 days prior to, during, or within 90 days after starting tuberculosis treatment,
(efavirenz group), or other ART regimens (non-efavirenz group). Patients who started ART more than 90 days
after initiation of TB treatment, or who experienced ART interruption of more than 15 days during TB treatment were
excluded. We describe rates and factors associated with death, virological suppression, and loss to follow up at
12 months using univariate, multivariate Cox, and marginal structural models to compare the two groups of patients.
Results: Of 965 patients (647 receiving efavirenz-containing ART, and 318 a non-efavirenz regimen) 50% were from EE,
28% from WE, and 22% from LA. Among those not receiving efavirenz-containing ART, regimens mainly contained a
ritonavir-boosted protease inhibitor (57%), or raltegravir (22%). At 12 months 1.4% of patients in WE had died,
compared to 20% in EE: rates of virological suppression ranged from 21% in EE to 61% in WE. After adjusting
for potential confounders, rates of death (adjusted Hazard Ratio; aHR, 95%CI: 1.13, 0.72–1.78), virological suppression
(aHR, 95%CI: 0.97, 0.76–1.22), and loss to follow up (aHR, 95%CI: 1.17, 0.81–1.67), were similar in patients treated with
efavirenz and non-efavirenz containing ART regimens.
Conclusion: In this large, prospective cohort, the response to ART varied significantly across geographical regions,
whereas the ART regimen (efavirenz or non-efavirenz containing) did not impact on the proportion of patients who
were virologically-suppressed, lost to follow up or dead at 12 months.
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Background
Globally, tuberculosis (TB) is the commonest opportunis-
tic infection in HIV-infected patients, especially in
resource-constrained settings [1]. Mortality in co-infected
patients varies across regions as reported previously [2, 3],
however, in most regions TB is the most common cause
of death among the HIV-infected adult population [4–6].
Prospective cohort studies demonstrated that HIV pa-
tients co-infected with TB have an increased risk of death
[5], and reduced mortality with appropriate TB treatment
and initiation of antiretroviral therapy (ART) [7, 8]. Add-
itionally, in patients with TB who present with advanced
immunodeficiency (CD4 count < 200 cells/mm3), early
initiation of ART (< 8 weeks after TB treatment initiation)
increases survival, as demonstrated in several large clinical
trials [9–12]. Efavirenz-based regimens were used in all of
these studies [9–12]. The efficacy of other ART regimens
in TB/HIV co-infected patients, and the relative efficacy of
rifampicin- or rifabutin-containing regimens in patients
receiving ART remains poorly studied [13–15]. Hence,
National and regional guidelines provide minimal guid-
ance on such ART regimens used concomitantly with tu-
berculosis treatment [1, 16–22].
On the other hand, late presentation of HIV-positive
adult patients into care is common in both resource-
constrained and high-income settings [23–25] and epi-
sodes of opportunistic infection including TB, may occur
within the first few months after initiation of ART [8].
In most parts of the world with limited resources and a
high burden of TB, efavirenz remains the preferred agent
as the third component of ART regimens, as it has no
clinically-significant interaction with rifampicin [1, 26].
However, tolerability and non-nucleoside reverse tran-
scriptase inhibitor resistance may preclude use of efavir-
enz. In 2007, the WHO recommended increasing the
ritonavir boosting dose to 400 mg every 12 h with lopi-
navir when concomitantly used in combination with
rifampicin [21] however this has been associated with
poor tolerability and hepatotoxicity [27–29]. More
recently, raltegravir was reported to be an adequate
alternative to efavirenz in TB/HIV co-infected patients
in a phase 2 trial [30]. Therefore, CDC and WHO both
indicate raltegravir to be the preferred option when efa-
virenz is contraindicated, or the use of rifabutin when
ritonavir-boosted protease inhibitors are necessary [1,
16, 18, 31]. However, access to rifabutin and raltegravir
in low- and middle-income countries, is often difficult
or impossible [30]. The aim of this study was to assess
clinical outcomes (mortality, virological suppression, loss
to follow-up during the first year following TB diagnosis)
across different regions (Eastern Europe, Western
Europe, and Latin America) among HIV-positive adult
patients treated with efavirenz and non-efavirenz con-
taining ART regimens.
Methods
Study population
The TB:HIV study is a collaboration between TB and
HIV clinicians from 19 countries in Europe and Latin
America. Patients aged 16 years or older were included
if they were HIV-positive and were diagnosed with TB
between January 1, 2011, and December 31, 2013. Pa-
tients with confirmed TB (Mycobacterium tuberculosis
on culture or PCR), probable TB (Acid-Fast Bacilli on
‘smear’ or granulomatous inflammation on biopsy speci-
mens) and presumptive TB (empiric TB treatment initi-
ated, and with a TB diagnosis not subsequently ruled
out) were included in the study. Details of the TB:HIV
study have been published elsewhere [2]. For the main
analysis, those who initiated tuberculosis treatment
and ART concomitantly were analyzed. Data on TB
and HIV disease, including demographic, clinical,
laboratory parameters, and clinical outcomes were
collected prospectively on standardized case report
forms (http://www.cphiv.dk). Due to the observational
nature of the study, all decisions regarding use of tu-
berculosis and ART treatment regimens was at the
discretion of individual clinicians.
Statistical analyses
In this study, patients were categorized into two groups
according to their ART regimen. In the efavirenz group
patients who initiated an efavirenz-containing ART regi-
men within 3 months of starting TB therapy, or who
were receiving it (at least in the 2 weeks before TB diag-
nosis) were included. Patients, who interrupted ART for
more than 15 days while on anti-TB drugs, were ex-
cluded. In the non-efavirenz group, patients receiving
ART but not containing efavirenz within the above time
frame were included. Patients in this group included
those in receipt of ritonavir-boosted protease inhibitors,
triple nucleoside reverse transcriptase inhibitors, inte-
grase inhibitors or nevirapine. Baseline was considered
the date anti-TB treatment was commenced. Demo-
graphic and clinical characteristics of patients at baseline
were described by receipt of ART in each region and for
all study participants. Patients were recorded as dead, in
care with virological suppression, in care without viro-
logical suppression, in care without viral load informa-
tion, or lost to follow up at 12 months after their TB
diagnosis. A viral load < 400 copies/mL between 8
and 12 months after baseline was considered as
virological suppression. Patients with a last visit date
reported before 12 months of follow-up were consid-
ered lost to follow up. All patients were included in
analysis of time to outcome, and were censored
12 months after the TB diagnosis.
The main outcome was mortality during the first
year following TB diagnosis comparing efavirenz and
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non-efavirenz containing ART regimens, using three
different statistical methods to account for potential
confounders and bias: inverse probability weighting,
Cox models and marginal structural models. For the
first method, Kaplan-Meier survival curves were esti-
mated using inverse weighting. Weights were calcu-
lated from a logistic model to predict efavirenz use,
adjusting by traditional confounders: region, age, gender,
CD4 count at TB diagnosis, type of TB, route of HIV
transmission, naïve status, rifamycin use (rifampicin or
rifabutin), and multidrug-resistant TB (MDR-TB). In the
second method, a Cox model was used to estimate risk of
death using the same co-variables, stratifying by naïve sta-
tus. Continuous variables such as age and CD4 cell count
were included in the models using splines with three
knots to fit a non-linear and less biased relationship with
the outcome [32]. Finally, a marginal structural model was
used to estimate the effect of both ART regimes on
mortality in the presence of varying time co-variables
(time-dependent confounders), as well as type of rifamycin
used, CD4 count, and resistance to anti-TB drugs (vari-
ables that could affect choice of ART regimen). With this
method, simulation of a clinical trial comparing two
regimes of ART in HIV individuals co-infected with
TB, controlling by time updated measurements of the
confounders, was attempted. To achieve this, a
monthly data set was generated for each patient se-
lected from the time of TB diagnosis until 12 months
of follow-up, recording all the socio-demographic and
clinical endpoints month by month.
Following standard use of marginal structural models,
patients who did not receive ART at initiation of TB
treatment were included in this analysis since, as they
were on tuberculosis treatment, they had the potential
to be started by clinicians on ART with any regimen, as
in local clinical practice [33]. The dataset was expanded
in order to have the same patients and their characteris-
tics in either of two possible regimens of ART (efavir-
enz-containing, or not), and artificial censoring was
created to keep only the time in which patients did not
leave the regimen. To adjust for a potential bias due to
unbalance of co-variables in each regimen stabilized
weights from two logistic models were built to predict
use of ART controlling by time, age, gender, region,
naive status, rifamycin use, injection drug use (IDU) sta-
tus, type of TB (disseminated compared to pulmonary),
CD4 count, and MDR-TB. The probability of death was
estimated with a pooled logistic regression model using
the ART regimen, time in months, region, CD4 count,
gender, naïve status, MDR-TB status, with rifamycin re-
ceipt as a co-variable and with stabilized weights [33].
Sensitivity analysis was done including only ART-naïve
patients. Cox models adjusted by traditional confounders
were used, looking for factors related to virological
suppression among patients at 12 months after diagnosis
of TB who were in care with a viral load available, and
who were lost to follow up.
Results
Of 1389 patients in the study, 965 (69%) received ART
during the predefined time-frame and were included in
the main analysis: 647 were in the efavirenz group and
318 in the non-efavirenz group. We excluded 177
patients because they started ART after the time-frame
(i.e. > 3 months after initiation of TB treatment), and 18
because of ART interruptions (> 15 days) during TB
treatment. Baseline characteristics of participants strati-
fied by ART regimen and ART status are shown in
Table 1. Patients were treated with a rifamycin (rifampin
or rifabutin) for a median of 7 months (IQR: 2–10). Pa-
tients had a median of one viral load measurement dur-
ing the first year following ART initiation (IQR: 0–2).
Clinical outcomes at 12 months
Mortality, the proportion of patients with undetectable viral
loads, and loss to follow up was similar for patients receiv-
ing efavirenz and non-efavirenz ART regimens, irrespective
of whether patients were ART-naïve or ART-experienced at
TB diagnosis (Table 2). Clinical outcomes differed signifi-
cantly across regions, although within regions, similar out-
comes were observed for patients receiving efavirenz and
non-efavirenz ART regimens (Fig. 1). The highest propor-
tion of deaths and the lowest proportion of patients with
undetectable HIV viral loads at 12 months were observed
in EE. Many patients in all regions had no viral load infor-
mation in the time window 8–12 months following TB
diagnosis: 25% in EE, 17% in WE, and 23% in LA) for those
receiving an efavirenz-containing regimen (p < 0.01), and
32%, 15% and 25% for those taking a non-efavirenz
regimen, respectively (p < 0.01) (Fig. 1).
Survival
By 12 months 113(12%) deaths had occurred: 84(13%)
in the efavirenz group and 29(9%) in the non-
efavirenz group. Using an inverse probability weight-
ing method, no difference in survival (adjusted by re-
gion, age, gender, CD4 count at TB diagnosis, type of
TB, route of HIV transmission, naïve status, rifamycin
use at TB diagnosis, and MDR-TB) was observed be-
tween efavirenz and non-efavirenz treated individuals
(Additional file 1: Figure S1). In adjusted Cox regres-
sion models stratified by ART status and use of rifa-
mycin, the hazard ratio (HR) for death was 1.13 (95%
CI: 0.72–1.78; p = 0.59) for efavirenz compared with
non-efavirenz ART regimens (Table 3). In the same
model, higher CD4 counts at TB diagnosis were associated
with a lower risk of death (HR 0.27, 95%CI: 0.17–0.42,
p < 0.001) for patients with CD4 of 350 cells/mm3
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compared to those with CD4 50 cells/mm3, and naïve
patients had a lower risk of death (HR 0.64, 95%CI: 0.43–
0.96, p = 0.03) (Table 3). Gender, age, route of HIV
transmission, disseminated TB, and MDR-TB were not
significantly associated with mortality. Survival analysis
stratified by ART status showed lower mortality among
naïve compared with non-naïve patients, but there were
no differences between patients receiving either efavir-
enz or non-efavirenz ART regimens (Additional file 1:
Figure S2).
Table 1 Demographic and clinical characteristics of patients at the time of starting TB therapy
All (N = 965) ART naïve (N = 518) Non ART naïve (N = 447)
Efavirenz
(n = 647)
non Efavirenz
(n = 318)
Efavirenz
(n = 420)
non Efavirenz
(n = 98)
Efavirenz
(n = 227)
non Efavirenz
(n = 220)
Patient age at TB diagnosis (years) 37 (31–43) 37 (31–45) 37 (32–44) 35 (32–43) 36 (31–42) 38 (31–47)
Male*, n(%) 499 (77%) 206 (65%) 345 (82%) 73 (74%) 154 (68%) 133 (60%)
Ethnic group, n(%)*+&
White 432 (68%) 182 (60%) 298 (73%) 61 (68%) 134 (60%) 121 (56%)
Hispanic 118 (19%) 43 (14%) 63 (15%) 10 (11%) 55 (25%) 33 (15%)
Black 47 (7%) 62 (20%) 26 (6%) 14 (16%) 21 (9%) 48 (22%)
Other 35 (6%) 18 (6%) 22 (5%) 5 (6%) 13 (6%) 13 (6%)
HIV risk, n(%)*
non IDU 382 (59%) 211 (66%) 243 (58%) 56 (57%) 139 (61%) 155 (70%)
IDU 265 (41%) 107 (34%) 177 (42%) 42 (43%) 88 (39%) 65 (30%)
Region, n(%)*+&
Eastern Europe 363 (56%) 118 (37%) 262 (62%) 50 (51%) 101 (44%) 68 (31%)
Western/Southern Europe 131 (20%) 144 (45%) 77 (18%) 39 (40%) 54 (24%) 105 (48%)
Latin America 153 (24%) 56(18%) 81 (19%) 9 (9%) 72 (32%) 47 (21%)
CD4+ count (cells/mm3)*+ 96 (33–210) 118 (34–310) 82 (29–164) 60 (18–118) 140(48–297) 168(56–372)
Missing CD4 counts, n (%) 3 (< 1%) 1 (< 1%) 3 (1%) 1 (1%) 0(0%) 0(0%)
HIV RNA (copies/mL), n(%)* < 400 76 (12%) 63(20%) 8 (2%) 2 (2%) 68 (30%) 61 (28%)
400–10 0000 39 (6%) 36 (11%) 18 (4%) 4 (4%) 21 (9%) 32 (14%)
> 10 0000 319 (49%) 121 (38%) 254(60%) 61 (62%) 65 (29%) 60 (27%)
Unknown 213 (33%) 98 (31%) 140 (33%) 31 (32%) 73 (32%) 67 (30%)
Haemoglobin (g/dL) 12 (10–14) 12 (10–14) 12 (10–14) 12 (10–13) 13 (10–14) 12 (10–14)
Disseminated TB+, n(%) 373 (58%) 189 (59%) 74 (76%) 237 (56%) 136 (60%) 115 (52%)
Resistance test performed 348 (54%) 169 (53%) 226 (54%) 49 (50%) 122 (54%) 120 (54%)
MDR-TB, n(%)° 68 (19%) 20 (12%) 47 (21%) 12 (24%) 21 (17%) 8 (7%)
Initial anti-TB drug, n(%)*+&
Rifampicin 587 (91%) 208 (65%) 390 (93%) 70 (71%) 197 (87%) 138 (63%)
Rifabutin 13 (2%) 69 (22%) 9 (2%) 12 (12%) 4 (2%) 57 (26%)
No rifamicin 47 (7%) 41 (13%) 21 (5%) 16 (16%) 26 (11%) 25 (11%)
ART regimen, n (%)
Efavirenz 647 (100%) 0 (0%) 420 (100%) 0 (0%) 227 (100%) 0 (0%)
Protease inhibitor 0 (0%) 181 (57%) 0 (0%) 62 (63%) 0 (0%) 119 (54%)
Integrase inhibitor 0 (0%) 70 (22%) 0 (0%) 23 (23%) 0 (0%) 47 (21%)
Other 0 (0%) 67 (21%) 0 (0%) 13 (13%) 0 (0%) 54 (25%)
Time between TB therapy and ART initiation (days)& – – 28 (17–49) 28 (15–34) 376 (47–1198) 1337 (199–3484)
Note: Continuous variables are reported as medians and interquartile ranges. *p < 0.05 between patients receiving efavirenz and non-efavirenz -containing regimens of
ART including the entire cohort. +p < 0.05 between efavirenz and non-efavirenz-containing ART regimens, including only naïve patients
&p < 0.05 between efavirenz and non-efavirenz including only non-naïve patients. Time between TB diagnosis and ART initiation was estimated between non-naïve
patients as TB diagnosis date less first ART date. °Percentage estimated relative to those with resistance test performed
IDU Injecting Drug User, MDR-TB Multi-drug resistant tuberculosis
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Marginal structural models
Of the 1389 patients in the prospective HIV:TB study
229(16.5%) never started ART and were therefore, only
included in the marginal structural model. Of these 229
patients 92% were from EE, 4% from WE and 3% LA. Their
median CD4 cell count was 149 cells/uL. 60% were IDU,
38% had MDR-TB and 65% had disseminated TB (see
Additional file 1: Table S2). Overall 117(51%) died, and at
12 months after TB diagnosis 75(33%) were lost to follow
up. Using the marginal structural model the odds of death
(OR) for those in receipt of an efavirenz-containing ART
regimen was 0.82 (95%CI: 0.66–1.02, p = 0.08, when com-
pared to those receiving a non-efavirenz containing regi-
men. After truncating weights for different percentiles, such
as 95%, the mortality odds remained non-significant
(OR 0.85 (95%CI: 0.67–1.07, p = 0.18). These results,
obtained using this model were consistent with the
other statistical techniques used in this study.
Furthermore exploration, in an analysis restricted to
patients starting efavirenz compared with those start-
ing a ritonavir-boosted protease inhibitor regimen
only, showed that the odds of death for those who
started an efavirenz-containing ART regimen was sta-
tistically better (OR 0.76, 95%CI: 0.60–0.95, p = 0.01).
Sensitivity analysis for mortality among ART-naïve
patients
This analysis included 518 ART-naïve patients: 420
(81%) receiving efavirenz-based ART and 98 (19%)
non-efavirenz containing ART. Adjusted survival curves
are shown in Additional file 1: Figure S3 and the Cox
model results are shown in Additional file 1: Table S1. In
the marginal structural model, odds of death were better
in those receiving efavirenz-based ART: OR 0.55 (95%CI:
Table 2 Outcomes at 12 months in the entire cohort, naïve and non-naïve patients, by ART regimen
All ART naïve ART non-naïve
Efavirenz (n = 647) non Efavirenz (n = 318) Efavirenz (n = 420) non Efavirenz (n = 98) Efavirenz (n = 227) non Efavirenz (n = 220)
Death 84 (13%) 29 (9%) 51 (12%) 10 (10%) 33 (14%) 19 (9%)
LTFU 129 (20%) 50 (16%) 100 (24%) 20 (20%) 29 (13%) 30 (14%)
Undetectable
HIV-RNA
220 (34%) 132 (41%) 134 (32%) 35 (36%) 86 (38%) 97 (44%)
Detectable HIV-
RNA
67 (11%) 34 (11%) 44 (10%) 8 (8%) 23 (10%) 26 (12%)
Active no VL 147 (23%) 73 (23%) 91 (22%) 25 (25%) 56 (25%) 48 (22%)
p value 0.08 0.78 0.27
Note: p values reflect the comparison of the overall distribution of outcomes for efavirenz- and non-efavirenz containing ART regimens
LTFU lost to follow-up, HIV-RNA Undetectable VL < 400 at 12 months, VL viral load
Fig. 1 Outcomes at 12 months by region and ART regimen. EFV: Efavirenz, LTFU: loss to follow-up. HIV-RNA undetectable: VL < 400
copies/ml at 12 months
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0.36–0.85, p < 0.01). Truncating at other percentiles
showed similar results. Additional file 1: Figure S4 and
Table S3 show the results for ART-non naïve patients.
Virological suppression
Among 453 of the original 965 patients who still were
alive and in care at 12 months, and who had viral load in-
formation available, 352 (77%) patients had undetectable
plasma HIV viral loads (less than 400 copies/ml). The pro-
portion of patients with virological suppression was less
frequent in EE, regardless of the ART regimen, compared
to the other regions. Distribution by ART regimen and
treatment experience is shown in Table 2. In an adjusted
Cox model, the hazard ratio (HR) for virological suppres-
sion was 0.97 (95%CI: 0.76–1.22: p = 0.77) for efavirenz,
compared with non-efavirenz containing ART regimens.
Gender, age, route of HIV transmission, disseminated TB,
rifamycin use, being ART-naïve, and having documented
MDR-TB were not significantly associated with virological
suppression (Table 4).
Loss to follow-up
Of the 852 patients included in this analysis, which only
excluded patients who died, 179 (21%) were lost to
follow up at 12 months (Table 2). In a Cox model, ad-
justed for gender, age, region, CD4 count at diagnosis of
TB, loss to follow-up was similar among those receiving
an efavirenz-containing regimen of ART, when com-
pared with non-efavirenz containing regimens: HR 1.17
(95% CI: 0.81–1.67: p = 0.40). However, a higher risk of
loss to follow-up was found in patients from EE,
compared to patients from other regions (Table 5).
Discussion
In this prospective observational study, there were major
differences in outcomes that were predicated by patients’
region of residence. The mortality in Eastern Europe
was significantly higher than in other regions, as
described previously [3, 34, 35], but this did not differ
significantly according to ART regimen (either efavirenz
or non-efavirenz containing ART). Although ART-naïve
patients had slightly better survival in comparison to
ART non-naïve patients, this was similar for patients re-
ceiving efavirenz and non-efavirenz containing ART reg-
imens. Furthermore, the proportions of patients who
became lost to follow up and who had undetectable viral
loads at 12 months following diagnosis of TB did not
Table 3 Risk factors for death. Univariate and multivariate Cox models
Univariate model Multivariate model
Hazard Ratio (95% confidence interval) p-value Hazard Ratio (95% confidence interval) p-value
Region < 0.01 < 0.01
Eastern Europe 1 1
Western/Southern Europe 0.16(0.08–0.31) 0.19 (0.09–0.39)
Latin America 0.42(0.25–0.70) 0.44 (0.25–0.77)
Age, years 0.69 0.87
30 vs 20 1.07(0.64–1.80) 1.12 (0.64–1.97)
40 vs 20 1.07(0.47–2.42) 1.29 (0.53–3.13)
50 vs 20 0.93(0.43–2.00) 1.53 (0.66–3.55)
Male 1.26(0.81–1.95) 0.30 1.00 (0.62–1.60) 0.99
Disseminated TB 1.57(1.06–2.33) 0.03 1.38 (0.92–2.06) 0.12
IDU 1.89(1.31–2.74) < 0.01 1.19 (0.78–1.83) 0.42
TB susceptibility < 0.01 0.52
No MDR vs MDR 0.41(0.24–0.71) 0.72 (0.41–1.27)
No Resistance test vs MDR 0.52(0.31–0.88) 0.84(0.49–1.46)
Efavirenz 1.47(0.96–2.24) 0.07 1.13(0.72–1.78) 0.59
ART naïve 1.06(0.73–1.54) 0.74 0.64(0.43–0.96) 0.03
CD4+ at TB diagnosis (cells/mm3) < 0.01 < 0.01
100 vs 50 0.63(0.53–0.76) 0.61(0.50–0.73)
200 vs 50 0.35(0.25–0.51) 0.33(0.23–0.48)
350 vs 50 0.27(0.17–0.42) 0.27(0.17–0.42)
Note: Cox regression model in which patients were stratified by rifamicin use at TB diagnosis
Nine hundred sixty-five patients were included in this model. IDU Injection Drug User, MDR-TB Multi-drug resistant tuberculosis
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differ according to whether efavirenz was included in
the ART regimen.
The observed similar survival in patients treated with
efavirenz or non-efavirenz regimens may have several
explanations, including that the non-efavirenz group was
heterogeneous. Although inverse probability weighting
was used to balance the differences in the co-variables
between groups, it is possible that not all confounders
including socio-demographic factors, comorbidities and/
or concomitant (opportunistic) infections, diagnostic
delay, and access to anti-TB drug susceptibility tests
were included. In contrast with previously described
findings in this cohort, MDR-TB was not associated with
mortality at 12 months, probably because those with
MDR-TB were less likely to start antiretroviral therapy
and were therefore not included in the current study:
moreover, a resistance test was performed in only 54% of
the selected population. In the main model used, no dif-
ferences in mortality between regimes was observed, but
in an explorative marginal structural model restricted
just to patients treated with a boosted protease inhibitor
or efavirenz, survival was statistically different, favoring
the group receiving efavirenz-based ART. This finding
may reflect poorer tolerability of protease inhibitors,
greater frequency of drug-drug interactions, or previous
virological failure that could additionally impact on mor-
tality. Surprisingly, there was a high proportion of sub-
jects receiving PI-based ART as their first regimen
(57%). This group of patients were mostly in the Eastern
European region (61%), and most likely the reason for
initiating ART with a PI-containing regimen was
because of the local availability. Moreover, only 22% of
those on non-efavirenz regimens received integrase
inhibitors, a majority from Western Europe. Any infer-
ences based on outcomes with this class of ART should
be interpreted with caution as the study was not
designed to directly compare integrase inhibitors with
efavirenz, and additionally, the main analysis may have
lacked power to detect a survival benefit.
The proportion of patients who were lost to follow up
was high, especially among patients from Eastern Eur-
ope, irrespective of ART regimen. This is consistent with
findings from other studies in countries with a high bur-
den of TB [36]. Higher rates of loss to follow up in some
other studies may be explained by differences in patient
populations, health care provision models including
Table 4 Factors associated with virological success
Univariate model Multivariate model
Hazard Ratio (95% confidence interval) p-value Hazard Ratio (95% confidence interval) p-value
Region 0.07 < 0.01
Eastern Europe 1 1
Western/Southern Europe 0.99(0.77–1.27) 1.03 (0.75–1.41)
Latin America 1.29(0.97–1.73) 1.42 (1.04–1.94)
Age, years 0.59 0.87
30 vs 20 1.13(084–1.52) 1.12 (0.83–1.51)
40 vs 20 1.24(0.76–2.02) 1.22 (0.74–2.01)
50 vs 20 1.26(0.80–2.00) 1.28 (0.80–2.06)
Male 1.01(0.81–1.27) 0.91 0.93 (0.73–1.18) 0.53
Disseminated TB 0.90(0.73–1.12) 0.34 0.86 (0.69–1.07) 0.17
IDU 1.07(0.85–1.34) 0.58 1.16 (0.87–1.55) 0.30
TB susceptibility 0.79 0.84
No MDR vs MDR 1.07(0.65–1.75) 1.05(0.62–1.78)
No Resistance test vs MDR 1.04(0.63–1.72) 0.98(0.58–1.66)
Rifamicin 1.25(0.79–1.97) 0.33
Efavirenz 1.05(0.84–1.30) 0.68 0.97(0.76–1.22) 0.77
ART naïve 1.11(0.90–1.37) 0.33 1.09(0.86–1.39) 0.44
CD4+ at TB diagnosis (cells/mm3) 0.48 0.41
100 vs 50 0.99(0.90–1.08) 0.99(0.90–1.10)
200 vs 50 0.96(0.79–1.16) 0.98(0.79–1.20)
350 vs 50 0.91(0.73–1.14) 0.92(0.73–1.17)
Note: Only 453 patients in care at 12 months were included in this model. Patients without HIV-RNA information were excluded, n = 220
IDU Injection Drug User, MDR-TB Multi-drug resistant tuberculosis
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more assertive outreach to patients who have dropped
out of care. Although frequency of patients with viro-
logical suppression at 12 month was overall acceptable
(77%), the proportion of plasma HIV-RNA determina-
tions was heterogeneous between regions. Nevertheless,
if the goal is to reach the 90–90-90 target, this rate of
virological suppression is still some way from being
accomplished. No clinical factors associated with an un-
detectable HIV viral load were found in this study, how-
ever it was less likely to be achieved in Eastern Europe.
In general, unfavorable outcomes such as loss to follow-
up, proportion of detectable viral load and mortality
were more frequent in the Eastern European region,
which is consistent with previous publications from our
study [2, 3]. Factors such as characteristics of the HIV
population (i.e. the high proportion of IDU), education
and health care barriers, less access to HIV monitoring
such as HIV-RNA determinations, and the feasibility of
implementing current recommendations on ART initi-
ation in the context of an AIDS-defining event [37],
might have an important role when patients are com-
pared with other regions with limited healthcare re-
sources, such as Latin America.
Our study has several limitations. These include the
relatively short follow-up period, differences between
regions in terms of routine care such as access to
HIV-RNA determinations, heterogeneity of use of
ART, availability of rifabutin and integrase inhibitors,
and timing of ART initiation at TB diagnosis. In
terms of data availability, we recognize limitations in
information regarding reasons for initiating or chan-
ging specific ART regimens, which did not allow us
to accurately distinguish between changes due to ad-
verse effects or changes due to ART failure and we
cannot exclude the possibility that some naïve pa-
tients might have been receiving ART – although this
was not detected during our quality assurance proce-
dures. However, this is the largest multi-regional TB:
HIV cohort and the first to comprehensively compare
the concomitant use of TB treatment and efavirenz
and non-efavirenz containing ART regimes. Using
marginal structural models, there was a slightly better
outcome for patients treated with efavirenz-containing
ART, although this was not consistent in all analyses
and therefore not categorical. These results warrant
further analyses.
Table 5 Risk factors for loss to follow-up
Univariate model Multivariate model
Hazard Ratio (95% confidence interval) p-value Hazard Ratio (95% confidence interval) p-value
Region < 0.01 < 0.01
Eastern Europe 1 1
Western/Southern Europe 0.59(0.41–0.84) 0.77(0.50–1.16)
Latin America 0.58(0.39–0.87) 0.64(0.41–1.00)
Age, years 0.59 a
30 vs 20 1.20(0.79–1.83)
40 vs 20 1.20(0.63–2.29)
50 vs 20 0.82(0.85–1.50)
Male 1.00(0.73–1.40) 0.96 0.90(0.64–1.28) 0.56
Disseminated TB 0.89(0.66–1.19) 0.44 0.93(0.68–1.26) 0.62
IDU 1.25(0.93–1.69) 0.13 0.97(0.68–1.37) 0.85
TB susceptibility 0.52 0.84
No MDR vs MDR 0.72(0.41–1.26) 0.92(0.51–1.65)
No Resistance test vs MDR 1.19(0.69–2.05) 1.45(0.83–2.52)
Rifamicin 0.84(0.50–1.41) 0.51 a
Efavirenz 1.38(0.99–1.91) 0.06 1.17(0.81–1.67) 0.40
ART naïve 1.94(1.42–2.65) < 0.01 a
CD4+ at TB diagnosis (cells/mm3) 0.48 0.41
100 vs 50 0.97(0.86–1.10) 0.99(0.90–1.10)
200 vs 50 0.95(0.73–1.25) 0.98(0.79–1.20)
350 vs 50 0.98(0.72–1.34) 0.92(0.73–1.17)
Note: Multivariate Cox model regression stratified by ryfamicin use, naïve condition and age. aFor these variables the model was stratified so we do not have
specific hazard ratios. Eight hundred fifty-two patients included, only people who died at 12 months were excluded in this model
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Conclusions
In this multi-centre, multi-region cohort study, overall,
poor outcomes were more frequent in Eastern Europe.
Use of efavirenz or non-efavirenz containing ART regi-
mens did not impact on mortality, virological suppres-
sion, or loss to follow-up at 12 months following
diagnosis of TB. Considering these differences between
regions irrespective of ART regimen, more, prospective
studies are needed, particularly in resource-constrained
regions in which access to rifabutin and integrase inhibi-
tors is still limited.
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